Bayer Zydus Pharma operates in key segments of the Indian pharmaceuticals market with a strong and successful product list.
This area provides access to press releases and media interaction.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. The group employs over 16,500 people worldwide including over 1200 scientists engaged in R & D and is dedicated to creating healthier communities globally. As a leading healthcare provider, it aims to become a global research based pharmaceutical company by 2020.
Zydus is one of the oldest players in the Indian formulations market. Besides continuously improving its market presence and market share, the group has also expanded its portfolio by entering newer therapeutic areas. The group has been launching new products with the first mover advantage and has a strong presence in both acute and chronic therapies. These strategic initiatives have helped Zydus become one of the dominant players in the Indian formulations market with the leadership position in several therapeutic categories.
The group has built strong positions in key segments of Cardiovasculars, Gastrointestinals, Women’s Healthcare and holds leading positions in other therapeutic segments such as Respiratory, Dermatology, Pain Management and Anti-infectives.
The group’s Zydus Discovery is dedicated to marketing the innovative NCE therapy Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia. Zydus Biovation, a superspecialty division, markets the world’s first biosimilar of Adalimumab to treat inflammatory arthritis. This includes Rheumatoid Arthritis, Ankylosing’s spondylitis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis(JIA). Zydus BioNext also markets this therapy for other indications such as Crohn’s disease and Ulcerative Collitis.
To Zydus Cadila website